• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tandem reels in $115m from public offering

August 8, 2018 By Sarah Faulkner

Tandem DiabetesTandem Diabetes Care (NSDQ:TNDM) said today that it raised roughly $115 million from an underwritten public offering.

The San Diego, Calif.-based company offered 3,508,770 shares of its common stock at $28.50 apiece. Underwriters fully exercised an option to buy 526,315 additional shares of common stock, Tandem noted.

Also today, the company announced that results from the Prolog study of its t:slim X2 insulin pump with predictive low glucose suspend technology were published online in Diabetes Care.

Data from the study show that Tandem’s t:slim X2 pump with Basal-IQ technology significantly reduced hypoglycemia without rebound hyperglycemia compared to the t:slim X2 pump with integrated CGM and no automated insulin suspension.

“The results seen in the Prolog study demonstrate that an automated insulin delivery system can have a significant impact on glycemic control without being overly complicated or burdensome for the patient,” principal investigator Dr. Greg Forlenza said in prepared remarks. “We think the t:slim X2 Insulin Pump with Basal-IQ Technology will be a welcome addition for healthcare providers and clinics looking for a simple-to-teach system that can help reduce the risk of hypoglycemia without significantly increasing the training and support demands on their practice.”

“Subjects in the Prolog study adopted the Basal-IQ system quickly and easily. There was also no evidence of alarm fatigue, since alerts related to insulin suspension and resumption are optional, allowing the feature to operate quietly in the background,” Dr. Jordan Pinsker, senior research physician at Sansum Diabetes Research Institute, added. “The high usability scores are remarkable and match the level of positive user experience feedback we received from participants over the course of the study.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS